Written by Ad OpsIntroduction and Overview
Apollo 11 (CBD) is a CBD-forward reinterpretation of the classic Apollo 11, engineered to retain the uplifting citrus-pine personality of the original while delivering a gentler, more functional experience. As suggested by the context details, the target strain is Apollo 11 (CBD), and live market information under that exact name can be limited or localized. In practice, the label often refers to CBD-rich selections or crosses built from Apollo 11 genetics and a high-CBD donor line. This article consolidates what growers, labs, and knowledgeable retailers report, aligning those insights with core cannabis science to give a clear, data-informed profile.
Where the traditional Apollo 11 is a zesty, terpinolene-leaning hybrid with clear-headed energy, the CBD variant typically trades peak psychoactivity for balance and composure. Consumers often describe a calm, productive clarity with minimal intoxication, a profile that suits daytime use and people sensitive to THC. Cultivators appreciate that it grows with Apollo’s trim-friendly structure, while the CBD influence can slightly modify internodal spacing and resin texture. Expect nuanced citrus, pineapple, and herbal-pine notes with an airy sweetness after the grind.
This guide drills into the history, breeding logic, appearance, aroma, flavor, cannabinoid and terpene chemistry, experiential effects, potential medical uses, and a comprehensive cultivation blueprint. We anchor claims with reported lab ranges where available and broader, published cannabinoid science where specific COAs are scarce. Each section is structured for quick scanning and deep reference, with actionable details for both consumers and cultivators. The goal is an authoritative, practical resource on Apollo 11 (CBD).
History and Origin
The classic Apollo 11 traces back to The Brothers Grimm, blending the famed “Genius” (a Jack Herer selection) with Cinderella 99. It built a reputation for bright terpinolene-driven citrus, brisk mental energy, and efficient flowering times around eight to nine weeks. That legacy made Apollo 11 a prime candidate to “convert” into a CBD-forward expression during the 2010s wave of CBD breeding. Breeders sought to keep the fresh, uplifting vibe while softening the THC punch for broader daytime and therapeutic compatibility.
Apollo 11 (CBD) is not a single, universally standardized cultivar but rather a category of related selections. Breeders typically introduce a high-CBD parent such as Cannatonic, AC/DC, or CBD Therapy, then stabilize for CBD-rich ratios through successive selections. The stated goal is often a 1:1 to CBD-dominant chemotype that preserves Apollo’s citrus-pine bouquet and productive mood. Because these efforts emerged from multiple breeders, market naming can vary slightly by region and seed supplier.
By the late 2010s and early 2020s, dispensary menus and small-batch growers began listing Apollo 11 CBD phenotypes with lab-verified CBD content. Publicly available COAs under this exact name are not abundant, but reported ranges align with other CBD-rich conversions of terpinolene-heavy lines. As legalization expanded, this niche gained traction among consumers seeking Apollo’s flavor with subtler intoxication. Today, Apollo 11 (CBD) occupies the “functional CBD hybrid” segment alongside notable 1:1 and 2:1 strains.
Genetic Lineage and Breeding
At its core, Apollo 11 (CBD) starts with the Apollo 11 backbone: Genius (a Jack Herer derivative) crossed to Cinderella 99. To introduce CBD, breeders commonly outcross to a CBD donor known to carry the functional CBDAS gene, such as Cannatonic or AC/DC. The fundamental genetic objective is to promote the CBD synthase allele so the plant diverts more CBGA to CBDA instead of THCA. Marker-assisted selection can accelerate this, but many breeders still rely on extensive phenotyping and lab testing.
When a high-THC parent is crossed with a high-CBD parent, the F1 often yields a spread of chemotypes: THC-dominant, balanced 1:1, and CBD-dominant. In an F2 population, Mendelian expectations for synthase alleles can approximate a 1:2:1 distribution for THC:balanced:CBD phenotypes, although real-world outcomes vary with linked traits and selection. Breeders aiming for consistent CBD dominance frequently backcross to the CBD donor or intermate best 1:1 selections, then stabilize through filial generations. Each generation is typically verified with small-batch COAs to confirm the cannabinoid ratio target.
The terroir of Apollo’s terpinolene-heavy aroma presents a unique breeding challenge. Terpinolene dominance can be diluted when crossing to CBD donors that lean myrcene or caryophyllene. Skilled breeders select individuals that retain citrus-pine and light tropical notes while meeting CBD targets, often rejecting otherwise high-CBD plants that lose Apollo’s bright, coniferous signature. The result is a CBD selection that still “smells like Apollo.”
In the market, you may encounter Apollo 11 (CBD) phenotypes advertised as 1:1 or 2:1 CBD:THC. Both reflect the breeding logic described and the variability inherent to multi-source seed pools. For consistency, many cultivators now keep their favorite CBD phenotype as a clone-only mother. That approach stabilizes aroma and cannabinoid output across successive crops.
Appearance and Morphology
Apollo 11 (CBD) typically exhibits medium stature with a strong central cola and cooperative lateral branching. Internodal spacing often ranges from tight to moderate, helping flowers stack into spears rather than golf balls. The buds are medium-dense, with calyx-forward formation that trims quickly and minimizes leaf waste. Trichome coverage is generous, though CBD-leaning phenotypes can appear slightly less “frosted” than THC-dominant Apollo 11.
Coloration is usually vibrant lime to forest green with sunrise-orange pistils. Under cooler nighttime temperatures, especially late in flower, some phenotypes may display faint lavender hues along sugar leaves. Resin heads tend to be medium in size with a slightly waxier, less sticky feel compared to high-THC Apollo cuts. This texture often correlates with less “gluey” handling during trimming but still robust terpene output.
Plants respond well to topping and low-stress training, forming flat canopies ideal for SCROG. Stem rigidity is adequate, yet large colas may benefit from netting during weeks 6–9 of flower. Expected flower time is 56–70 days depending on phenotype and environment, with CBD-dominant expressions trending on the longer side. Outdoors, harvest commonly lands late September to mid-October in temperate zones.
Aroma Profile
The aroma profile leans fresh and effusive, with citrus zest, pineapple-candy overtones, and a piney conifer core. Many phenotypes add sweet herbal hints reminiscent of lemongrass, basil, or sweet hay. Breaking the flower unlocks a sharper top note of terpinolene and limonene, which often reads as lime rind, tart apple, or clean pine-sol brightness. The background can show traces of ocimene’s floral-fruity lift.
In pre-grind form, the bouquet is pleasant but not overpowering, often a 6 or 7 on a 10-point intensity scale. After grinding, intensity jumps one to two points, with the citrus-herbal plume filling a small room quickly. Consumers frequently note that the scent is “bright without being dank,” indicating a lean toward volatile top notes rather than skunky thiols. Dry-down leaves a whisper of pine and sweet citrus pith.
CBD crosses can bend the aromatic balance toward earth and tea if the CBD donor leans myrcene. Careful selection maintains Apollo’s hallmark citrus-pine by favoring terpinolene-forward individuals. When cured well, terpinolene stays crisp for months, though poor storage accelerates fade. Expect a clear, uplifting bouquet if terpene preservation is prioritized.
Flavor Profile
The flavor follows the nose with crisp citrus and pine, but adds a soft, sweet fruit note on the inhale. Some cuts show pineapple-citrus candy up front, while others skew toward lime rind and dewy herbs. On exhale, a pine-sap and mild pepper finish suggests caryophyllene in supporting amounts. Vaporization at 180–195°C highlights the citrus-herbal spectrum without singeing terpenes.
Combustion preserves flavor if the cure is slow and moisture content is balanced around 10–11%. Consumers often score the flavor as clean and refreshing with minimal throat bite, particularly in the 1:1 phenotypes. As the bowl progresses, sweetness recedes and a spruce-needle dryness emerges in the background. Water-cured or over-dried samples can taste flat, emphasizing why controlled humidity is essential.
Pairing-wise, Apollo 11 (CBD) complements unsweetened green tea, citrus seltzer, or light pilsners that echo its zesty elements. Terpinolene-rich cultivars pair neatly with bright foods like ceviche, grapefruit, or fresh basil salads. Avoid heavy, sugar-dense snacks that can mask the delicate top notes. A clean device and low-to-moderate temperature preserve the nuanced palate best.
Cannabinoid Profile
Because Apollo 11 (CBD) refers to CBD-forward selections of Apollo 11, cannabinoid ranges vary with breeder and phenotype. Reported lab tests for comparable CBD-rich hybrids indicate CBD between 6–16% by weight and THC between 0.3–8%, with total cannabinoids often clustering in the 12–22% range. Balanced 1:1 phenotypes commonly show 6–10% CBD and 6–10% THC, while CBD-dominant 2:1 or higher can reach 10–16% CBD with 1–6% THC. Outliers exist, but most Apollo 11 (CBD) cuts used for daytime function fall within those bands.
From a dosage standpoint, a flower at 12% CBD contains about 120 mg CBD per gram and approximately 2–6% THC would contribute 20–60 mg THC per gram. Consumers using small inhalation doses of 50–100 mg flower may ingest 6–12 mg CBD and 1–6 mg THC, depending on the exact ratio and device efficiency. Vaporizer extraction efficiencies can range 40–70%, while combustion can be lower and more variable. These numbers help frame expected intake without relying on edibles math.
Decarboxylation converts THCA and CBDA to their active forms, with typical mass loss of 12–15% due to CO2 release. For home extraction, decarbing ground flower at 105–115°C for 30–45 minutes is commonly used to activate cannabinoids while preserving terpenes. Longer decarb increases activation but can volatilize terpenes and oxidize cannabinoids. Lab testing after processing is the only way to confirm final potency accurately.
A small subset of CBD-dominant phenotypes may flirt with hemp compliance (<0.3% total THC by dry weight), but many Apollo 11 (CBD) expressions exceed that threshold and are regulated as cannabis. Always confirm with a current certificate of analysis before assuming compliance status. Batch-to-batch variability is normal, especially in early breeding generations. Clonal propagation from a verified mother reduces potency drift dramatically.
Terpene Profile
Apollo 11’s lineage often generates a terpinolene-forward chemotype, and many CBD conversions preserve that trait. In reported tests for comparable Apollo-derived CBD hybrids, total terpene content frequently ranges 1.0–2.5% by weight (10–25 mg/g), with some exceptional indoor batches surpassing 3.0%. Typical dominant terpenes include terpinolene (0.3–6.0 mg/g), beta-myrcene (2.0–5.0 mg/g), limonene (1.0–3.0 mg/g), beta-caryophyllene (1.0–2.0 mg/g), and ocimene (0.5–1.5 mg/g). Minor contributors often include linalool (0.2–0.8 mg/g), alpha-pinene (0.3–0.9 mg/g), and humulene (0.3–0.8 mg/g).
Terpinolene and limonene provide the citrus-zest and green-apple lift, while myrcene lends a soft, herbal cushioning. Caryophyllene adds a peppery, woody edge and binds to CB2 receptors, which some users associate with a soothing body presence. Ocimene contributes floral-fruity, slightly tropical aromatics that amplify the pineapple suggestion in Apollo 11. Linalool, even at modest levels, can round the finish with faint lavender sweetness.
Terpene stability depends heavily on post-harvest handling. Studies show that exposure to light and oxygen can reduce volatile terpene content by 20–30% over 90 days in poorly sealed containers. Storing in amber glass with minimal headspace at cool temperatures slows degradation significantly. Humidity control around 58–62% helps maintain both flavor and combustion smoothness.
Aromachemistry also shifts with cure length. Early (7–10 day) cures emphasize terpinolene’s sharp citrus, while longer cures (3–6 weeks) often mellow the top notes and accent the pine and pepper base. Growers who target a bright, zesty profile often jar earlier and burp more frequently to preserve tops. Those seeking a rounder, tea-like complexity let the cure stretch and stabilize.
Experiential Effects
Apollo 11 (CBD) is prized for its clear-headed, low-anxiety demeanor and functional daytime usability. Many report a calm, gently uplifting onset within minutes of inhalation, accompanied by mental clarity and a subtle mood boost. Body sensation is typically light to medium, without the heavy sedation common to myrcene-dominant CBD cultivars. The tempered THC content reduces the chance of racing thoughts for sensitive consumers.
In balanced 1:1 phenotypes, the experience can feel more dynamic, with a touch of euphoria and enhanced sensory awareness. CBD-dominant expressions lean steadier and more grounding, favoring focus tasks, creative ideation, and social ease. Duration is often 90–150 minutes via inhalation, with a steady taper rather than a steep comedown. Edible or tincture preparations extend duration but slow onset.
Subjective reports align with broader CBD literature suggesting that CBD may buffer some THC-induced adverse effects. Users who find classic Apollo 11 too racy often appreciate Apollo 11 (CBD) for similar flavor with less edge. This makes it an approachable entry for those cautious about intoxication. It is also a popular “reset” strain between heavier night-time options.
Potential Medical Uses
While strain-specific clinical trials are rare, Apollo 11 (CBD) fits profiles explored in broader cannabinoid research. CBD has been studied for anxiolytic potential, with a 2019 retrospective case series reporting that 79.2% of patients experienced decreased anxiety scores in the first month and 66.7% saw improved sleep. Balanced CBD:THC medicines, such as oromucosal sprays with near 1:1 ratios, have demonstrated benefit for multiple sclerosis spasticity, with clinically meaningful improvement observed in a sizable subset of patients. These findings provide context for why 1:1 Apollo 11 (CBD) phenotypes are popular among wellness users.
For pain, observational data and randomized trials suggest cannabinoids may reduce chronic pain intensity modestly, with effect sizes varying by condition. CBD’s anti-inflammatory mechanisms via TRPV1, adenosine, and cytokine modulation are frequently cited, while THC contributes central analgesia and mood elevation. A CBD-dominant Apollo 11 can be appealing for daytime discomfort because it offers body relief with minimal intoxication. The terpinolene-limonene profile may also support perceived alertness compared to myrcene-heavy options.
Sleep impacts are dose-dependent. Low to moderate CBD doses can be alerting in some individuals, while higher doses may aid sleep latency indirectly by reducing anxiety. The 2019 case series noted sustained sleep improvements in many patients, but real-world outcomes vary. For nighttime use, some prefer pairing Apollo 11 (CBD) with a more sedating cultivar or adjusting dose timing.
CBD can interact with CYP450 enzymes, potentially affecting medications such as warfarin, clobazam, or certain SSRIs. Individuals with complex medical regimens should consult a clinician knowledgeable in cannabinoid pharmacology before regular use. As always, start low and go slow, particularly for THC-sensitive users. Lab testing is essential to confirm the actual CBD:THC ratio before therapeutic planning.
